Parotid tumors Market Analysis
The global parotid tumors market is predicted to grow at a 7.1% CAGR over the forecast period (2017-2023), as per the latest Market Research Future (MRFR) report. Parotid tumors are the most common form of salivary gland tumors. It accounts for about 85% of all salivary gland tumors. These tumors are mostly noncancerous.
Free Sample PDF Available Here!! https://www.marketresearchfuture.com/sample_request/5678
The parotid glands are prone to cancers, parotitis, parotid tumors, injury, and fibrous reaction. A parotid tumor is an abnormal growth in the salivary gland which is caused by numerous factors such as metastasis of cancer, salivary duct stones, dehydration, salivary gland infections, abdominal surgery, and liver cirrhosis. The human body has two parotid glands on each side of the face. Parotid tumors are usually slow and benign, yet in rare cases, it can be malignant. Some of its common symptoms include swelling or mass in the jaw area that may or may not be accompanied by pain. In the case of malignant tumors, this may affect facial nerves resulting in numbness, pain, loss of movement in the face, or prickling/burning sensation.
Various factors are propelling the parotid tumors market growth. These factors, as stated by the MRFR report, include the rising prevalence of cancer, rising alcohol consumption, and growing incidences of liver cirrhosis. Additional factors pushing market growth include growing market players providing new products, growing demand for advanced technologies, and government support and initiatives.
On the contrary, the various complications arising post treatment such as cosmetic deformity, infection, and hemorrhage or hematoma are factors that may hinder the parotid tumors market growth over the forecast period.
The Market Research Future report provides a wide segmental analysis of the parotid tumors market based on type, treatment, end users, and diagnosis.
Based on type, the parotid tumors market is segmented into cancerous/malignant tumor, pleomorphic adenoma, and Warthin’s tumor. Of these, pleomorphic adenoma is the common type of parotid tumor. It is also known as a benign mixed tumor.
Based on treatment, the parotid tumors market is segmented into chemotherapy, reconstructive surgery, radiation therapy, parotidectomy, and removal of the lymph node. Of these, the parotidectomy segment will have the largest share in the market over the forecast period.
Based on diagnosis, the parotid tumors market is segmented into sialography, fine needle aspiration cytology, ultrasound, MRI, CT scan, X-ray, and others.
Based on end-users, the parotid tumors market is segmented into research centers, hospitals, and specialty centers.
Based on the region, the parotid tumors market report covers growth opportunities and the latest trends across Europe, North America, Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, North America will lead the market over the forecast period. This is owing to rising alcohol consumption and an increasing number of cancer cases. Besides, the increasing expenditure on healthcare is also likely to boost the market growth.
The parotid tumors market in Europe is predicted to have a noticeable growth over the forecast period. This is owing to the burgeoning need for healthcare infrastructure, availability of skilled medical professionals, and availability of advanced treatment.
The parotid tumors market in the APAC region is predicted to grow at the fastest pace over the forecast period. This is owing to the rising prevalence of chronic diseases. India is a key contributor in this region owing to the accessibility of new treatments and rising concern about health.
The parotid tumors market in the Middle East and Africa is predicted to have a slow growth over the forecast period due to limited access to treatment and lack of awareness.
Leading players profiled in the parotid tumors market report include Eli Lilly & Co, Merck & Co. Inc., Hoffmann-La Roche Ltd, Bayer AG, Janssen Global Services LLC, Bristol-Myers Squibb, Pfizer Inc., and Novartis AG.
July 2019: The human medicines committee of EMA’s (European Medicines Agency) has suggested the conditional approval for the very first medicine for treating tumors having a specific mutation, irrespective of where the tumor in the body originated. This treatment is ideal for both pediatric and adult patients alike having solid tumors, including salivary gland tumors, infantile fibrosarcoma, and common diseases such as colon and lung cancer.
OBTAIN RESEARCH REPORT DETAILS WITH TOC @ https://www.marketresearchfuture.com/reports/parotid-tumors-market-5678
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar